Saturday, 17 October 2026European Markets

INTEROIL EXPL PROD Stock 15.03% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with INTEROIL EXPL PROD (IOX.OL) rising 15.03% to kr0.88 on Monday, following the last session's upward trend. Oslo Børs Benchmark Index_GI rose 0.85% to kr1,293.99, following the last session's downward trend on what was a somewhat bullish trend exchanging session today.

INTEROIL EXPL PROD's last close was kr0.77, 40.61% under its 52-week high of kr1.29.

About INTEROIL EXPL PROD

Interoil Exploration and Production ASA, together with its subsidiaries, operates as an upstream oil exploration and production company. It engages in the acquisition, exploration, development, and operation of oil and natural gas properties. The company's portfolio includes two producing concessions and two exploration concessions in Colombia; and one exploration and seven production concessions in Argentina. Interoil Exploration and Production ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, INTEROIL EXPL PROD has a trailing twelve months EPS of kr-0.32.

More news about INTEROIL EXPL PROD (IOX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com